黄体功能不全 中国就医指南

Luteal Phase Deficiency (LPD), also known as luteal phase defect or inadequate luteal phase, is a reproductive endocrine disorder characterized by insufficient progesterone production or impaired endometrial response during the luteal phase—the period between ovulation and the onset of menstruation. A healthy luteal phase typically lasts 12–14 days and requires adequate progesterone secretion from the corpus luteum to support endometrial maturation, embryo implantation, and early pregnancy maintenance. LPD is diagnosed when the luteal phase is shortened (<10 days), serum progesterone levels are suboptimal (e.g., <10 ng/mL on day 21 of a 28-day cycle), or endometrial biopsy reveals histologic dating lagging >2 days behind expected menstrual cycle timing. Pathophysiologically, LPD may arise from multiple interrelated mechanisms: hypothalamic-pituitary dysfunction leading to inadequate luteinizing hormone (LH) surge amplitude or duration; premature luteolysis due to excessive prostaglandins or oxidative stress; ovarian aging or diminished ovarian reserve impairing corpus luteum function; or endometrial resistance to progesterone caused by inflammation, genetic polymorphisms (e.g., in progesterone receptor genes), or chronic conditions like thyroid autoimmunity or hyperprolactinemia. Epidemiologically, LPD remains challenging to quantify precisely due to diagnostic variability and lack of standardized criteria; however, studies estimate its prevalence among women with unexplained infertility at 3–10%, and up to 25% among those with recurrent pregnancy loss. Risk factors include high-intensity exercise, significant weight loss or low BMI, chronic stress, polycystic ovary syndrome (PCOS), thyroid disorders (especially subclinical hypothyroidism), hyperprolactinemia, advanced maternal age (>35 years), and prior ovarian surgery. Importantly, LPD is not a standalone disease but rather a functional biomarker reflecting underlying endocrine or ovarian dysregulation. Quality of life impact is substantial yet often underrecognized: patients frequently experience emotional distress—including anxiety, frustration, and grief—due to repeated implantation failure or miscarriage; disrupted sexual intimacy related to timed intercourse protocols; financial strain from repeated fertility treatments; and social isolation stemming from stigma around infertility. While LPD itself does not cause overt systemic symptoms, associated manifestations may include short menstrual cycles, premenstrual spotting, recurrent early pregnancy loss, or difficulty conceiving despite regular ovulation. Diagnosis requires integrated assessment: serial mid-luteal serum progesterone measurements, transvaginal ultrasound for follicular tracking and endometrial thickness/echogenicity, and sometimes hormonal profiling (LH, FSH, estradiol, prolactin, TSH, AMH). Accurate diagnosis is essential to avoid unnecessary treatment and guide targeted interventions.

# 黄体功能不全治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：初诊、轻中度LUF、备孕早期、无器质性病变者

• •基础支持：黄体酮胶囊（口服）或地屈孕酮片，周期第14–28天，3–6个月疗程

• •联合用药：HCG肌注（排卵后48h起，隔日1次×3次）+黄体酮阴道缓释凝胶

• •配套检查：血清P、E₂、LH动态监测（月经周期D21±2）、甲状腺功能、胰岛素抵抗评估

二、微创/核心介入方案

适用人群：反复生化妊娠、IVF周期黄体支持失败、明确存在卵巢储备下降伴LUF

• •个体化黄体支持优化：经阴道超声引导下黄体期子宫内膜容受性评估（ERA）+精准黄体酮剂量滴定

- 全套干预（含ERA检测、基因表达分析、定制化给药方案）：8,500–14,200元/周期

三、特殊复杂情况方案

适用人群：合并PCOS、高泌乳素血症、自身免疫性黄体衰竭或多次ART失败者

• •多靶点干预（溴隐亭+二甲双胍+个体化黄体支持+免疫调节如低分子肝素）

方案快速选择指南

• •预算≤5,000元/年：首选国产黄体酮+基础激素监测（方案一基础档）
• •备孕紧迫/既往流产≥2次：推荐HCG联合阴道黄体酮+D21血P复查（方案一进阶档）
• •IVF周期失败≥2次：直接启动ERA指导下的微创精准支持（方案二）
• •合并代谢/免疫异常：进入多学科联合管理路径（方案三）